Trial Profile
Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2015
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Dec 2015 New trial record